Raia Drogasil S.A. Logo

Raia Drogasil S.A.

RADL3.SA

(2.8)
Stock Price

25,22 BRL

5.54% ROA

17.37% ROE

41.17x PER

Market Cap.

42.775.319.978,00 BRL

107.99% DER

1.46% Yield

2.86% NPM

Raia Drogasil S.A. Stock Analysis

Raia Drogasil S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Raia Drogasil S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (19.58%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

5 ROA

The stock's ROA (6.16%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (963) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 PBV

The stock's high Price-to-Book Value (P/BV) ratio (8.07x) suggests it's overvalued, potentially making it an expensive investment.

9 DER

The stock is burdened with a heavy load of debt (123%), making it financially unstable and potentially risky for investors.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Raia Drogasil S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Raia Drogasil S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Raia Drogasil S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Raia Drogasil S.A. Revenue
Year Revenue Growth
2003 344.673.000
2004 426.918.000 19.26%
2005 539.166.000 20.82%
2006 674.425.000 20.06%
2007 833.069.000 19.04%
2008 1.260.147.000 33.89%
2009 1.720.548.000 26.76%
2010 2.005.216.000 14.2%
2011 2.729.392.000 26.53%
2012 5.380.728.000 49.27%
2013 6.232.919.000 13.67%
2014 7.391.569.000 15.68%
2015 8.897.849.000 16.93%
2016 11.256.565.000 20.95%
2017 13.212.505.000 14.8%
2018 14.801.445.000 10.74%
2019 17.565.600.000 15.74%
2020 20.066.840.000 12.46%
2021 24.127.002.000 16.83%
2022 29.067.380.000 17%
2023 34.703.236.000 16.24%
2023 33.973.790.000 -2.15%
2024 38.748.880.000 12.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Raia Drogasil S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Raia Drogasil S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 16.693.000
2004 17.638.000 5.36%
2005 22.188.000 20.51%
2006 3.218.000 -589.5%
2007 26.965.000 88.07%
2008 40.372.000 33.21%
2009 56.234.000 28.21%
2010 51.694.000 -8.78%
2011 0 0%
2012 171.450.000 100%
2013 176.463.000 2.84%
2014 194.958.000 9.49%
2015 235.088.000 17.07%
2016 297.729.000 21.04%
2017 328.664.000 9.41%
2018 416.481.000 21.09%
2019 548.713.000 24.1%
2020 699.757.000 21.59%
2021 912.334.000 23.3%
2022 1.249.847.000 27%
2023 1.552.500.000 19.49%
2023 1.503.526.000 -3.26%
2024 1.523.156.000 1.29%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Raia Drogasil S.A. EBITDA
Year EBITDA Growth
2003 22.890.000
2004 23.592.000 2.98%
2005 23.405.000 -0.8%
2006 57.827.000 59.53%
2007 50.361.000 -14.82%
2008 49.453.000 -1.84%
2009 131.849.000 62.49%
2010 157.636.000 16.36%
2011 157.676.000 0.03%
2012 284.212.000 44.52%
2013 300.305.000 5.36%
2014 490.727.000 38.8%
2015 666.323.000 26.35%
2016 885.044.000 24.71%
2017 1.027.929.000 13.9%
2018 1.099.871.000 6.54%
2019 1.826.108.000 39.77%
2020 2.031.478.000 10.11%
2021 2.549.501.000 20.32%
2022 2.995.457.000 14.89%
2023 3.487.076.000 14.1%
2023 3.778.702.000 7.72%
2024 4.404.428.000 14.21%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Raia Drogasil S.A. Gross Profit
Year Gross Profit Growth
2003 107.609.000
2004 120.975.000 11.05%
2005 149.166.000 18.9%
2006 184.516.000 19.16%
2007 226.834.000 18.66%
2008 294.158.000 22.89%
2009 398.850.000 26.25%
2010 478.398.000 16.63%
2011 717.921.000 33.36%
2012 1.492.649.000 51.9%
2013 1.720.176.000 13.23%
2014 2.110.192.000 18.48%
2015 2.714.560.000 22.26%
2016 3.504.143.000 22.53%
2017 3.988.000.000 12.13%
2018 4.445.522.000 10.29%
2019 5.198.361.000 14.48%
2020 5.891.132.000 11.76%
2021 7.206.168.000 18.25%
2022 8.809.468.000 18.2%
2023 10.360.580.000 14.97%
2023 8.546.018.000 -21.23%
2024 9.934.932.000 13.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Raia Drogasil S.A. Net Profit
Year Net Profit Growth
2003 6.959.000
2004 7.951.000 12.48%
2005 9.725.000 18.24%
2006 20.795.000 53.23%
2007 21.626.000 3.84%
2008 51.173.000 57.74%
2009 74.590.000 31.39%
2010 89.015.000 16.21%
2011 68.696.000 -29.58%
2012 104.855.000 34.48%
2013 100.985.000 -3.83%
2014 221.386.000 54.39%
2015 340.206.000 34.93%
2016 447.685.000 24.01%
2017 511.163.000 12.42%
2018 502.447.000 -1.73%
2019 772.240.000 34.94%
2020 484.444.000 -59.41%
2021 751.934.000 35.57%
2022 996.112.000 24.51%
2023 1.054.740.000 5.56%
2023 1.054.973.000 0.02%
2024 1.306.524.000 19.25%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Raia Drogasil S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 1 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Raia Drogasil S.A. Free Cashflow
Year Free Cashflow Growth
2004 3.374.000
2005 2.339.000 -44.25%
2006 1.722.000 -35.83%
2007 -4.217.000 140.83%
2008 -60.640.000 93.05%
2009 24.378.000 348.75%
2010 -49.131.000 149.62%
2011 -55.086.000 10.81%
2012 -154.305.000 64.3%
2013 67.536.000 328.48%
2014 85.276.000 20.8%
2015 116.848.000 27.02%
2016 65.360.000 -78.78%
2017 -11.490.000 668.84%
2018 -20.119.000 42.89%
2019 678.565.000 102.96%
2020 800.817.000 15.27%
2021 694.949.000 -15.23%
2022 493.473.000 -40.83%
2023 -260.172.000 289.67%
2023 480.746.000 154.12%
2024 -26.769.000 1895.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Raia Drogasil S.A. Operating Cashflow
Year Operating Cashflow Growth
2004 11.066.000
2005 16.667.000 33.61%
2006 16.859.000 1.14%
2007 28.718.000 41.29%
2008 -24.463.000 217.39%
2009 74.232.000 132.95%
2010 52.446.000 -41.54%
2011 28.619.000 -83.26%
2012 105.334.000 72.83%
2013 305.743.000 65.55%
2014 359.926.000 15.05%
2015 501.695.000 28.26%
2016 555.529.000 9.69%
2017 628.840.000 11.66%
2018 682.866.000 7.91%
2019 965.211.000 29.25%
2020 1.477.238.000 34.66%
2021 1.550.545.000 4.73%
2022 1.682.255.000 7.83%
2023 88.893.000 -1792.45%
2023 1.785.327.000 95.02%
2024 252.648.000 -606.65%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Raia Drogasil S.A. Capital Expenditure
Year Capital Expenditure Growth
2004 7.692.000
2005 14.328.000 46.31%
2006 15.137.000 5.34%
2007 32.935.000 54.04%
2008 36.177.000 8.96%
2009 49.854.000 27.43%
2010 101.577.000 50.92%
2011 83.705.000 -21.35%
2012 259.639.000 67.76%
2013 238.207.000 -9%
2014 274.650.000 13.27%
2015 384.847.000 28.63%
2016 490.169.000 21.49%
2017 640.330.000 23.45%
2018 702.985.000 8.91%
2019 286.646.000 -145.25%
2020 676.421.000 57.62%
2021 855.596.000 20.94%
2022 1.188.782.000 28.03%
2023 349.065.000 -240.56%
2023 1.304.581.000 73.24%
2024 279.417.000 -366.89%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Raia Drogasil S.A. Equity
Year Equity Growth
2003 96.867.000
2004 101.525.000 4.59%
2005 67.217.000 -51.04%
2006 81.479.000 17.5%
2007 368.520.000 77.89%
2008 355.313.000 -3.72%
2009 407.615.000 12.83%
2010 598.617.000 31.91%
2011 2.201.174.000 72.8%
2012 1.211.597.000 -81.68%
2013 2.326.983.000 47.93%
2014 2.456.937.000 5.29%
2015 2.656.797.999 7.52%
2016 2.935.955.000 9.51%
2017 3.250.372.000 9.67%
2018 3.534.767.000 8.05%
2019 4.076.419.000 13.29%
2020 4.425.621.000 7.89%
2021 4.718.802.000 6.21%
2022 5.402.941.000 12.66%
2023 5.794.986.000 6.77%
2023 6.028.301.000 3.87%
2024 6.190.065.999 2.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Raia Drogasil S.A. Assets
Year Assets Growth
2003 166.252.000
2004 194.891.000 14.69%
2005 225.422.000 13.54%
2006 299.095.000 24.63%
2007 567.462.000 47.29%
2008 590.958.000 3.98%
2009 731.914.000 19.26%
2010 922.285.000 20.64%
2011 3.168.308.000 70.89%
2012 3.340.186.000 5.15%
2013 3.614.093.000 7.58%
2014 4.049.289.000 10.75%
2015 4.699.201.000 13.83%
2016 5.659.303.000 16.97%
2017 6.464.249.000 12.45%
2018 7.352.005.000 12.08%
2019 12.248.255.000 39.98%
2020 13.828.088.000 11.42%
2021 14.775.506.000 6.41%
2022 17.185.306.000 14.02%
2023 19.386.533.000 11.35%
2023 20.094.412.000 3.52%
2024 20.705.524.000 2.95%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Raia Drogasil S.A. Liabilities
Year Liabilities Growth
2003 69.385.000
2004 93.366.000 25.68%
2005 158.205.000 40.98%
2006 217.616.000 27.3%
2007 198.942.000 -9.39%
2008 235.645.000 15.58%
2009 324.299.000 27.34%
2010 323.668.000 -0.19%
2011 967.134.000 66.53%
2012 1.075.527.000 10.08%
2013 1.287.110.000 16.44%
2014 1.592.352.000 19.17%
2015 2.042.403.000 22.04%
2016 2.723.348.000 25%
2017 3.213.877.000 15.26%
2018 3.817.238.000 15.81%
2019 8.171.836.000 53.29%
2020 9.402.467.000 13.09%
2021 10.056.704.000 6.51%
2022 11.782.365.000 14.65%
2023 13.591.547.000 13.31%
2023 14.066.111.000 3.37%
2024 14.515.458.000 3.1%

Raia Drogasil S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
21.22
Net Income per Share
0.61
Price to Earning Ratio
41.17x
Price To Sales Ratio
1.18x
POCF Ratio
25.59
PFCF Ratio
97.08
Price to Book Ratio
6.93
EV to Sales
1.35
EV Over EBITDA
12.7
EV to Operating CashFlow
29.36
EV to FreeCashFlow
111.38
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
42,78 Bil.
Enterprise Value
49,08 Bil.
Graham Number
7.01
Graham NetNet
-4.73

Income Statement Metrics

Net Income per Share
0.61
Income Quality
1.55
ROE
0.17
Return On Assets
0.05
Return On Capital Employed
0.16
Net Income per EBT
0.8
EBT Per Ebit
0.62
Ebit per Revenue
0.06
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.26
Operating Profit Margin
0.06
Pretax Profit Margin
0.04
Net Profit Margin
0.03

Dividends

Dividend Yield
0.01
Dividend Yield %
1.46
Payout Ratio
0.46
Dividend Per Share
0.37

Operating Metrics

Operating Cashflow per Share
0.97
Free CashFlow per Share
0.26
Capex to Operating CashFlow
0.74
Capex to Revenue
0.03
Capex to Depreciation
0.7
Return on Invested Capital
0.14
Return on Tangible Assets
0.06
Days Sales Outstanding
29.19
Days Payables Outstanding
66.76
Days of Inventory on Hand
104.7
Receivables Turnover
12.5
Payables Turnover
5.47
Inventory Turnover
3.49
Capex per Share
0.72

Balance Sheet

Cash per Share
0,22
Book Value per Share
3,61
Tangible Book Value per Share
2.48
Shareholders Equity per Share
3.6
Interest Debt per Share
4.33
Debt to Equity
1.08
Debt to Assets
0.32
Net Debt to EBITDA
1.63
Current Ratio
1.51
Tangible Asset Value
4,25 Bil.
Net Current Asset Value
-2,57 Bil.
Invested Capital
12121154000
Working Capital
4,05 Bil.
Intangibles to Total Assets
0.09
Average Receivables
2,94 Bil.
Average Payables
5,26 Bil.
Average Inventory
7685439000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Raia Drogasil S.A. Dividends
Year Dividends Growth
2007 1
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Raia Drogasil S.A. Profile

About Raia Drogasil S.A.

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. As of March 31, 2022, the company operated a network of 2,530 drug stores in 26 Brazilian states. It also markets its goods through telesales and its three call centers in the states of São Paulo, Tocantins, and Pernambuco. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

CEO
Mr. Marcílio D'Amigo Pousada
Employee
59.341
Address
Av. Corifeu de Azevedo Marques, 3097
São Paulo, 05.339-900

Raia Drogasil S.A. Executives & BODs

Raia Drogasil S.A. Executives & BODs
# Name Age
1 Mr. Marcello De Zagottis
Vice President of Commercial & Marketing and Member of Executive Board
70
2 Celso Pissi Filho
Accountant & Technical Manager
70
3 Flavio Fogaca
Director of IR, Corporate Affairs & Strategy
70
4 Mr. Fernando Kozel Varela
Vice President of Digital Transformation & Member of Executive Board
70
5 Mr. Renato Cepollina Raduan
Vice President of Store, Multichannel & Expansion Operations and Member of Executive Board
70
6 Ms. Maria Susana De Souza
Vice President of People, Culture & Sustainability and Member of Executive Board
70
7 Mr. Bruno Wright Pipponzi
Vice President of Health Business & Member of Executive Board
70
8 Mr. Antonio Carlos Coelho
Vice President of Finance & Administrative and Member of Executive Board
70
9 Mr. Marcílio D'Amigo Pousada
Chief Executive Officer & Member of Executive Board
70

Raia Drogasil S.A. Competitors

Lojas Renner S.A. Logo
Lojas Renner S.A.

LREN3.SA

(2.0)
Hypera S.A. Logo
Hypera S.A.

HYPE3.SA

(3.8)
Fleury S.A. Logo
Fleury S.A.

FLRY3.SA

(2.8)
Localiza Rent a Car S.A. Logo
Localiza Rent a Car S.A.

RENT3.SA

(1.5)
WEG S.A. Logo
WEG S.A.

WEGE3.SA

(3.8)